Product Description
The 1G9-CP217 monoclonal antibody is a recombinant, chimeric version of the original 1G9 antibody. The variable domain sequences are identical but the constant region sequences are switched from Mouse IgG1, kappa to mouse IgG2a, kappa. The 1G9-CP217 antibody has an effector function competent Fc domain allowing for activation of Fcgamma receptors (FcgammaRs) to trigger antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) and opsonization to promote target cell depletion. The mouse IgG2a isotype demonstrates strong effector functions due to potent interaction with mFcgammaRIV, which is functionally similar to the FcgammaRIIIa receptor involved in human ADCC. Species-matched chimeric antibodies result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies. The 1G9-CP217 antibody reacts with mouse TIGIT (T cell immunoreceptor with Ig and ITIM domains). TIGIT is a 26 kDa, type I transmembrane protein and a member of the poliovirus receptor (PVR) family. TIGIT has been found to be expressed on follicular T helper cells in mice while in humans its expressed by many T cell subsets including activated T cells, follicular T helper cells, memory T cells, and regulatory T cells as well as on NK cells. TIGIT can interact with certain members of the PVR and PVR-like families, including PVR, PVRL2, PVRL3, CD155, and CD112. TIGIT is thought to negatively regulate NK and T cell activation. Binding TIGIT on T cells by dendritic cells results in their differentiation into a tolerogenic phenotype, with increased secretion of IL-10 and diminished production of IL-12.
* VAT and shipping costs not included. Errors and price changes excepted
